Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Evelo Biosciences, Inc. (EVLO) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Evelo Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1694665.
Total stock buying since 2018: $81,621,577.
Total stock sales since 2018: $142,288.
Total stock option exercises since 2018: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 5,411,255 | $12,499,999 | 236,394 | $126,778 | 510,384 | $0 |
| 2022 | 27,791,093 | $40,574,994 | 0 | $0 | 29,555 | $0 |
| 2021 | 130,000 | $1,950,000 | 0 | $0 | 29,554 | $0 |
| 2020 | 4,684,366 | $17,596,584 | 3,000 | $15,510 | 0 | $0 |
| 2018 | 562,500 | $9,000,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-11 | 0 | $0 | 25,956 | $8,560 | 58,297 | $0 |
| 2023-09 | 0 | $0 | 1,996 | $7,864 | 15,000 | $0 |
| 2023-08 | 0 | $0 | 8,908 | $84,714 | 20,796 | $0 |
| 2023-07 | 5,411,255 | $12,499,999 | 0 | $0 | 0 | $0 |
| 2023-05 | 0 | $0 | 199,383 | $25,480 | 415,937 | $0 |
| 2023-01 | 0 | $0 | 151 | $160 | 354 | $0 |
| 2022-06 | 0 | $0 | 0 | $0 | 4,927 | $0 |
| 2022-05 | 27,791,093 | $40,574,994 | 0 | $0 | 9,851 | $0 |
| 2022-03 | 0 | $0 | 0 | $0 | 4,926 | $0 |
| 2022-02 | 0 | $0 | 0 | $0 | 4,926 | $0 |
| 2022-01 | 0 | $0 | 0 | $0 | 4,925 | $0 |
| 2021-12 | 0 | $0 | 0 | $0 | 4,926 | $0 |
| 2021-11 | 0 | $0 | 0 | $0 | 9,851 | $0 |
| 2021-10 | 0 | $0 | 0 | $0 | 4,927 | $0 |
| 2021-09 | 0 | $0 | 0 | $0 | 9,850 | $0 |
| 2021-02 | 130,000 | $1,950,000 | 0 | $0 | 0 | $0 |
| 2020-12 | 7,700 | $52,152 | 3,000 | $15,510 | 0 | $0 |
| 2020-08 | 10,000 | $44,435 | 0 | $0 | 0 | $0 |
| 2020-06 | 4,666,666 | $17,499,997 | 0 | $0 | 0 | $0 |
| 2018-05 | 562,500 | $9,000,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-08 | Thorell Marella (Chief Financial Officer) | Sale | 1,811 | .33 | 597 |
| 2023-11-08 | Mchale Duncan (Chief Medical Officer) | Sale | 3,103 | .33 | 1,023 |
| 2023-11-08 | Bodmer Mark (CSO, President of R&D) | Sale | 3,163 | .33 | 1,043 |
| 2023-11-08 | Gill Simba (President & CEO) | Sale | 172 | .33 | 56 |
| 2023-11-07 | Thorell Marella (Chief Financial Officer) | Option Ex | 6,500 | .00 | 0 |
| 2023-11-07 | Mchale Duncan (Chief Medical Officer) | Option Ex | 6,500 | .00 | 0 |
| 2023-11-07 | Bodmer Mark (CSO, President of R&D) | Option Ex | 6,625 | .00 | 0 |
| 2023-11-07 | Gill Simba (President & CEO) | Option Ex | 1,172 | .00 | 0 |
| 2023-11-02 | Thorell Marella (Chief Financial Officer) | Sale | 3,999 | .33 | 1,319 |
| 2023-11-02 | Mchale Duncan (Chief Medical Officer) | Sale | 6,854 | .33 | 2,261 |
| 2023-11-02 | Bodmer Mark (CSO, President of R&D) | Sale | 6,854 | .33 | 2,261 |
| 2023-11-01 | Thorell Marella (Chief Financial Officer) | Option Ex | 12,500 | .00 | 0 |
| 2023-11-01 | Mchale Duncan (Chief Medical Officer) | Option Ex | 12,500 | .00 | 0 |
| 2023-11-01 | Bodmer Mark (CSO, President of R&D) | Option Ex | 12,500 | .00 | 0 |
| 2023-09-28 | Gill Simba (President & CEO) | Sale | 1,996 | 3.94 | 7,864 |
| 2023-09-27 | Gill Simba (President & CEO) | Option Ex | 15,000 | .00 | 0 |
| 2023-08-08 | Thorell Marella (Chief Financial Officer) | Sale | 2,004 | 9.51 | 19,058 |
| 2023-08-08 | Mchale Duncan (Chief Medical Officer) | Sale | 3,434 | 9.51 | 32,657 |
| 2023-08-08 | Bodmer Mark (CSO, President of R&D) | Sale | 3,128 | 9.51 | 29,747 |
| 2023-08-08 | Gill Simba (President & CEO) | Sale | 342 | 9.51 | 3,252 |
| 2023-08-07 | Thorell Marella (Chief Financial Officer) | Option Ex | 6,500 | .00 | 0 |
| 2023-08-07 | Mchale Duncan (Chief Medical Officer) | Option Ex | 6,500 | .00 | 0 |
| 2023-08-07 | Bodmer Mark (CSO, President of R&D) | Option Ex | 6,625 | .00 | 0 |
| 2023-08-07 | Gill Simba (President & CEO) | Option Ex | 1,171 | .00 | 0 |
| 2023-07-11 | Afeyan Noubar | Buy | 5,411,255 | 2.31 | 12,499,999 |
| 2023-05-23 | Bodmer Mark (CSO, President of R&D) | Sale | 22,571 | .14 | 3,205 |
| 2023-05-08 | Thorell Marella (Chief Financial Officer) | Sale | 38,531 | .13 | 4,854 |
| 2023-05-08 | Mchale Duncan (Chief Medical Officer) | Sale | 66,730 | .13 | 8,407 |
| 2023-05-08 | Bodmer Mark (CSO, President of R&D) | Sale | 68,014 | .13 | 8,569 |
| 2023-05-08 | Gill Simba (President & CEO) | Sale | 3,537 | .13 | 445 |
| 2023-05-07 | Thorell Marella (Chief Financial Officer) | Option Ex | 130,000 | .00 | 0 |
| 2023-05-07 | Mchale Duncan (Chief Medical Officer) | Option Ex | 130,000 | .00 | 0 |
| 2023-05-07 | Bodmer Mark (CSO, President of R&D) | Option Ex | 132,500 | .00 | 0 |
| 2023-05-07 | Gill Simba (President & CEO) | Option Ex | 23,437 | .00 | 0 |
| 2023-01-23 | Carriere Stephen J (Principal Accounting Officer) | Sale | 151 | 1.06 | 160 |
| 2023-01-19 | Carriere Stephen J (Principal Accounting Officer) | Option Ex | 354 | .00 | 0 |
| 2022-06-30 | Epstein David R | Option Ex | 4,927 | .00 | 0 |
| 2022-05-31 | Epstein David R | Option Ex | 4,925 | .00 | 0 |
| 2022-05-27 | Mchale Duncan (Chief Medical Officer) | Buy | 34,246 | 1.46 | 49,999 |
| 2022-05-27 | Darzi Lord Ara | Buy | 342,465 | 1.46 | 499,998 |
| 2022-05-27 | Epstein David R | Buy | 17,123 | 1.46 | 24,999 |
| 2022-05-27 | Afeyan Noubar (10% Owner) | Buy | 27,397,259 | 1.46 | 39,999,998 |
| 2022-05-02 | Epstein David R | Option Ex | 4,926 | .00 | 0 |
| 2022-03-31 | Epstein David R | Option Ex | 4,926 | .00 | 0 |
| 2022-02-28 | Epstein David R | Option Ex | 4,926 | .00 | 0 |
| 2022-01-31 | Epstein David R | Option Ex | 4,925 | .00 | 0 |
| 2021-12-31 | Epstein David R | Option Ex | 4,926 | .00 | 0 |
| 2021-11-30 | Epstein David R | Option Ex | 4,926 | .00 | 0 |
| 2021-11-01 | Epstein David R | Option Ex | 4,925 | .00 | 0 |
| 2021-10-01 | Epstein David R | Option Ex | 4,927 | .00 | 0 |
| 2021-09-03 | Epstein David R | Option Ex | 9,850 | .00 | 0 |
| 2021-02-02 | Afeyan Noubar (10% Owner) | Buy | 130,000 | 15.00 | 1,950,000 |
| 2020-12-11 | Epstein David R | Buy | 7,700 | 6.77 | 52,152 |
| 2020-12-01 | Liu Xiaoli Jacqueline (Principal Accounting Officer) | Sale | 3,000 | 5.17 | 15,510 |
| 2020-08-31 | Epstein David R | Buy | 5,752 | 4.50 | 25,872 |
| 2020-08-28 | Epstein David R | Buy | 4,248 | 4.37 | 18,563 |
| 2020-06-29 | Afeyan Noubar (10% Owner) | Buy | 4,666,666 | 3.75 | 17,499,997 |
| 2018-05-11 | Flagship Ventures Fund Iv-rx, L.p. (10% Owner) | Buy | 281,250 | 16.00 | 4,500,000 |
| 2018-05-11 | Kania Edwin M Jr (10% Owner) | Buy | 281,250 | 16.00 | 4,500,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of EVLO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Evelo Biosciences, Inc. (symbol EVLO, CIK number 1694665) see the Securities and Exchange Commission (SEC) website.